{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:49:08Z","timestamp":1783435748610,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21-CA259236"],"award-info":[{"award-number":["R21-CA259236"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K12-CA090628"],"award-info":[{"award-number":["K12-CA090628"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge. Primary endpoints were adverse events and sPD-L1 reduction. Secondary endpoints included overall survival, response, and progression-free survival. Correlative studies included changes in sPD-L1, other immunosuppressive factors, and immune cell phenotypes. Eighteen patients were included. Treatment was well-tolerated, and levels of sPD-L1 were reduced by TPE (mean 78%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Soluble PD-L1 suppression predicted overall survival. The overall response rate was 61% (16.7% complete, 44.4% partial, 22.2% stable, and 16.7% progressing). Changes in peripheral immune cell populations and immunosuppressive factors predicted overall survival. sPD-L1 and other circulating immunoregulatory molecules mediate ICI resistance. TPE can reduce these factors and resensitize ICI-refractory melanoma. Patients with persistent elevation or rapid rebound of sPD-L1 experienced inferior outcomes, suggesting that multiple courses of TPE may be necessary. These findings may apply to other ICI-resistant cancers. Trial registration: NCT04581382, ReCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-57865-9","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:50:44Z","timestamp":1741866644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0239","authenticated-orcid":false,"given":"Jacob J.","family":"Orme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Lingamaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddy","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dizona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hirdler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanina K.","family":"Gicobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kottschade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-5040","authenticated-orcid":false,"given":"Robert R.","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4219","authenticated-orcid":false,"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-4325","authenticated-orcid":false,"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana S.","family":"Dronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-2983","authenticated-orcid":false,"given":"Haidong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-345X","authenticated-orcid":false,"given":"Fabrice","family":"Lucien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie T.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-3732","authenticated-orcid":false,"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-853X","authenticated-orcid":false,"given":"Sean S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"57865_CR1","doi-asserted-by":"crossref","unstructured":"Dong H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002 [cited 2017 Oct 2];8:793. Available from: http:\/\/www.nature.com\/doifinder\/10.1038\/nm730.","DOI":"10.1038\/nm730"},{"key":"57865_CR2","doi-asserted-by":"crossref","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","DOI":"10.1056\/NEJMoa1503093"},{"key":"57865_CR3","doi-asserted-by":"publisher","unstructured":"Orme J. J. et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology 2020;9:https:\/\/doi.org\/10.1080\/2162402X.2020.1744980. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2020.1744980.","DOI":"10.1080\/2162402X.2020.1744980"},{"key":"57865_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00262-019-02437-2","volume":"69","author":"Y Romero","year":"2020","unstructured":"Romero, Y., Wise, R. & Zolkiewska, A. Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. Cancer Immunol. Immunother. 69, 43\u201355 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"57865_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","volume":"1","author":"X Frigola","year":"2011","unstructured":"Frigola, X. et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res Clin. Cancer Res. 1, 1915\u20131923, https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3241002\/pdf\/nihms274392.pdf (2011).","journal-title":"Clin. Cancer Res Clin. Cancer Res."},{"key":"57865_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.imlet.2018.01.007","volume":"196","author":"M Takeuchi","year":"2018","unstructured":"Takeuchi, M. et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol. Lett. 196, 155\u2013160 (2018).","journal-title":"Immunol. Lett."},{"key":"57865_CR7","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.21873\/anticanres.13716","volume":"39","author":"K Ando","year":"2019","unstructured":"Ando, K. et al. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Res. 39, 5195\u20135201, http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31519633 (2019).","journal-title":"Anticancer Res."},{"key":"57865_CR8","doi-asserted-by":"crossref","unstructured":"Dronca, R. S. et al. Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma. J. Clin. Oncol. 35, 11534 (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.11534"},{"key":"57865_CR9","first-page":"768","volume":"28","author":"R Dronca","year":"2015","unstructured":"Dronca, R. et al. Soluble PD-L1 (sPD-L1) is associated with decreased survival in metastatic melanoma. Pigment Cell Melanoma Res. 28, 768\u2013769, http:\/\/ovidsp.tx.ovid.com\/sp-3.30.0b\/ovidweb.cgi?QS2=434f4e1a73d37e8c9a99ba2905f8d89de218de2ed4420d3c473ce525e4150aa0354eace016cf6511029d1d0464f335dbebf164b10a4985393db8da4ac5609156301be3552b827ca3f5cee92481a4fa1d9a370152c9ffc91ca2718d161777ed1d97b5b4ac2a (2015).","journal-title":"Pigment Cell Melanoma Res."},{"key":"57865_CR10","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1111\/1759-7714.13721","volume":"11","author":"S Murakami","year":"2020","unstructured":"Murakami, S. et al. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thorac. Cancer 11, 3585\u20133595 (2020).","journal-title":"Thorac. Cancer"},{"key":"57865_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.07.028","volume":"148","author":"G Mazzaschi","year":"2020","unstructured":"Mazzaschi, G. et al. Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy-treated NSCLC patients. Lung Cancer 148, 1\u201311 (2020).","journal-title":"Lung Cancer"},{"key":"57865_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99311-y","volume":"11","author":"SY Oh","year":"2021","unstructured":"Oh, S. Y. et al. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci. Rep. 11, 19712 (2021).","journal-title":"Sci. Rep."},{"key":"57865_CR13","doi-asserted-by":"crossref","unstructured":"Yan, Y. et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 2018;3. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29669928.","DOI":"10.1172\/jci.insight.97828"},{"key":"57865_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijrobp.2018.09.001","volume":"103","author":"JD Evans","year":"2019","unstructured":"Evans, J. D. et al. Prospective Immunophenotyping of CD8+ T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT. Int J. Radiat. Oncol. Biol. Phys. 103, 229\u2013240, http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30205124 (2019).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"57865_CR15","doi-asserted-by":"crossref","unstructured":"Dronca R. S. et al. T cell Bim levels reflect responses to anti\u2013PD-1 cancer therapy. JCI Insight 2016;1. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4863706\/pdf\/jciinsight-1-86014.pdf.","DOI":"10.1172\/jci.insight.86014"},{"key":"57865_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2567.2007.02723.x","volume":"123","author":"G Zhang","year":"2008","unstructured":"Zhang, G. et al. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 123, 538\u2013546 (2008).","journal-title":"Immunology"},{"key":"57865_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/cimm.2000.1649","volume":"201","author":"MK Oaks","year":"2000","unstructured":"Oaks, M. K. et al. A native soluble form of CTLA-4. Cell Immunol. 201, 144\u2013153 (2000).","journal-title":"Cell Immunol."},{"key":"57865_CR18","doi-asserted-by":"crossref","unstructured":"Botticelli A. et al. The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study. J. Pers. Med. 11 (2021).","DOI":"10.3390\/jpm11070651"},{"key":"57865_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887916","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Soluble immune checkpoint-related proteins in blood are associated with invasion and progression in non-small cell lung cancer. Front. Immunol. 13, 887916 (2022).","journal-title":"Front. Immunol."},{"key":"57865_CR20","doi-asserted-by":"publisher","first-page":"34529","DOI":"10.1074\/jbc.M113.488478","volume":"288","author":"K M\u00f6ller-Hackbarth","year":"2013","unstructured":"M\u00f6ller-Hackbarth, K. et al. A Disintegrin and Metalloprotease (ADAM) 10 and ADAM17 are major Sheddases of T cell immunoglobulin and Mucin Domain 3 (Tim-3)*. J. Biol. Chem. 288, 34529\u201334544, https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925820554495 (2013).","journal-title":"J. Biol. Chem."},{"key":"57865_CR21","doi-asserted-by":"crossref","unstructured":"Kashyap S. et al. Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1\/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients. Br. J. Ophthalmol. (2023).","DOI":"10.1136\/bjo-2022-322913"},{"key":"57865_CR22","doi-asserted-by":"crossref","unstructured":"Orme J. J. et al. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J. Immunother. Cancer 8. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32817395 (2020).","DOI":"10.1136\/jitc-2020-001113"},{"key":"57865_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi2414","volume":"9","author":"JK Gicobi","year":"2023","unstructured":"Gicobi, J. K. et al. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation. Sci. Adv. 9, eadi2414 (2023).","journal-title":"Sci. Adv."},{"key":"57865_CR24","doi-asserted-by":"crossref","unstructured":"Zhang H. et al. Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in 11 C-Choline-PET\/CT-identified oligometastatic castration-resistant prostate cancer. Clin. Cancer Res. clincanres.2510.2021. Available from: http:\/\/clincancerres.aacrjournals.org\/lookup\/doi\/10.1158\/1078-0432.CCR-21-2510 (2021).","DOI":"10.1158\/1078-0432.CCR-21-2510"},{"key":"#cr-split#-57865_CR25.1","unstructured":"Lucien F. et al. Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity. Int. J. Radiat. Oncol. Biol. Phys. [cited 2022 Sep 25]"},{"key":"#cr-split#-57865_CR25.2","unstructured":"Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35671867\/ (2022)."},{"key":"57865_CR26","doi-asserted-by":"crossref","unstructured":"Yan Y. et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3 (2018).","DOI":"10.1172\/jci.insight.97828"},{"key":"57865_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4161\/onci.20850","volume":"1","author":"RM Gibbons","year":"2012","unstructured":"Gibbons, R. M. et al. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology 1, 1061\u20131073 (2012).","journal-title":"Oncoimmunology"},{"key":"57865_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2326-6066.CIR-21-0539","volume":"10","author":"T Wen","year":"2022","unstructured":"Wen, T. et al. NKG7 Is a T-cell-intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy. Cancer Immunol. Res. 10, 162\u2013181 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"57865_CR29","unstructured":"Orme J. J. et al. Source Data for Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial. FigShare. (2025)."},{"key":"57865_CR30","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde, A. et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat. Med 29, 2278\u20132285 (2023).","journal-title":"Nat. Med"},{"key":"57865_CR31","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","volume":"31","author":"CN Owen","year":"2020","unstructured":"Owen, C. N. et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy\u2606. Ann. Oncol. 31, 1075\u20131082 (2020).","journal-title":"Ann. Oncol."},{"key":"57865_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57865-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57865-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57865-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:50:53Z","timestamp":1741866653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57865-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["57865"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-57865-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4542220\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Intellectual property has been filed, addressing discoveries disclosed in this manuscript. J.J.O. reports support and\/or research and consulting support from the National Cancer Institute (R21 CA259236, K12 CA90628-23), Prostate Cancer Foundation, Mayo Lawrence W. and Marilyn W. Matteson Fund, NaNotics LLC, and Partner Therapeutics. L.K. reports consultant activities for Immunocore. M.S.B. reports institutional research support from Alkermes, Bristol-Myers Squibb, Genentech, Merck, nFerence, Perspective Therapeutics, Pharmacyclics, Regeneron, Sorrento, TILT Biotherapeutics, Transgene, and Viewpoint Molecular Therapeutics; as well as consultant activities for Sorrento Therapeutics, TILT Biotherapeutics, and Viewpoint Molecular Targeting; and receipt of drugs from Merck (pembrolizumab for an investigator-sponsored trial). A.S.M. reports grant funding from Novartis and Verily; support from Answers in CME, Antoni van Leeuwenhoek Kanker Instituut, AXIS Medical Education Inc, BeiGene, Chugai Pharmaceutical Co Ltd, Ideology Health LLC, Immunocore, Intellisphere LLC, Janssen, Johnson & Johnson Global Services, MJH Life Sciences, University of Miami Int\u2019l Mesothelioma Symposium; consulting activities with AbbVie, AstraZeneca, BMS, Genentech, Gilead, Janssen, Sanofi Genzyme, Rising Tide, Takeda Oncology, and TRIPTYCH Health Partners; study funding subsequent publication processing fees from Genentech, Janssen, BMS; steering committee member for Janssen and Johnson & Johnson Global Services; travel support from Roche; was a non-remunerated director of the Mesothelioma Applied Research Foundation and is a non-remunerated director of the Friends of Patan Hospital. D.S.C. reports honoraria from Targeted Oncology, GU Onc Live, Curio, MJH Life Sciences, IntrinsiQ, International Centers for Precision Oncology Foundation; consulting or advisory roles in Janssen Biotech (Inst), Novartis (Inst), Abdera (Inst); research funding from Janssen Biotech (Inst), Novartis (Inst). R.R.M. reports grant funding from GlaxoSmithKline and BMS. S.N.M. reports grant funding, clinical trial for BMS, and grant funding, as well as PI for Journey Therapeutics and Sorrento Pharma. M.D. reports personal stock of less than $5,000 in Pfizer. K.O. reports an honorarium from UptoDate. D.O. reports research support from AstraZeneca and Varian; as well as an honorarium from UptoDate. S.P. reports support from NCI R21 CA259236 and the Mayo Lawrence W. and Marilyn W. Matteson Fund. D.M. reports intellectual property from EXACT Sciences, InSitu Biologics, and CurrentHealth. F.L. reports receiving research support tothe institution from Nanotics LLC; serving as scientific consultant for Mursla Bio; and receiving royalties from Early is Good. J.W. reports support from NCI R21 CA259236 and Mayo Lawrence W. and Marilyn W. Matteson Fund and non-remunerated director of AABB, ASFA, and ISFA, as well as an advisory board position for DSMB (paid). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2507"}}